GelrinC benefits
Gelrin is an off-the-shelf, acellular hydrogel platform designed for cartilage repair, preventing cellular migration and aiding hyaline-like cartilage regeneration.
regentis.co.ilCrawled Nov 17, 2026
Gelrin is an off-the-shelf, acellular hydrogel platform designed for cartilage repair, preventing cellular migration and aiding hyaline-like cartilage regeneration.
A Pilot/Phase II study of 56 patients treated with GelrinC showed superior improvements in KOOS scores and pain subscale over four years in Northern Europe and Israel.
Gelrin is a patented hydrogel platform developed at the Technion – Israel Institute of Technology, using crosslinked polymer chains and denatured protein for erosion and resorption.
GelrinC is an acellular, biodegradable implant combining polyethylene glycol di-acrylate (PEG-DA) and denatured fibrinogen, crosslinked with UVA light to form a hydrogel matrix.
GelrinC is implanted in a single step after microfracture treatment, requiring about 10 minutes to apply the liquid hydrogel to fill cartilage defects.
Knee cartilage injuries, caused by acute or repetitive trauma, often fail to heal naturally and may lead to joint degeneration or osteoarthritis without treatment.
The company holds a patent portfolio of 34 issued patents, including 11 U.S. patents and 26 foreign patents, covering aspects of its product family.
Regentis Biomaterials develops hydrogel-based solutions for repairing damaged tissue, with a focus on orthopedic applications to restore patient health.
The company’s privacy policy outlines its online information practices and user choices to protect privacy on regentis.co.il and related sites.
The company prioritizes accessibility, ensuring its site meets Level AA of the W3C Web Content Accessibility Guidelines (WCAG) 2.0 for users with disabilities.